source
- Novo Nordisk CFO sees oral Wegovy rollout boosting outlook and remains upbeat on CagriSemaNovo Nordisk's chief financial officer, Karsten Munk Knudsen, discussed the company's second‑quarter earnings and the progress of the oral Wegovy pill during a recent interview. He highlighted that…
- Revolution Medicines sees strong demand for pancreatic cancer drug daraxonrasib under compassionate useRevolution Medicines reports that more than 2,000 patients have received its pancreatic cancer candidate daraxonrasib through a compassionate use program. The company says the drug has been distri…